烟草病学年度进展2023  

Annual progress in tobacco medicine in 2023

作　　者：刘朝[1] 肖丹[1] Liu Zhao;Xiao Dan(Department of Tobacco Control and Prevention of Respiratory Diseases,China-Japan Friendship Hospital,National Center for Respiratory Medicine,State Key Laboratory of Respiratory Health and Multimorbidity,National Clinical Research Center for Respiratory Diseases,Institute of Respiratory Medicine,Chinese Academy of Medical Sciences,World Health Organization Collaborating Centre for Tobacco Cessation and Respiratory Diseases Prevention,Beijing 100029,China)

机构地区：[1]中日友好医院控制吸烟与呼吸疾病防控部、国家呼吸医学中心、呼吸和共病全国重点实验室、国家呼吸系统疾病临床医学研究中心、中国医学科学院呼吸病学研究院、世界卫生组织戒烟与呼吸疾病预防合作中心,北京100029

出　　处：《中华结核和呼吸杂志》2024年第2期163-166,共4页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：中央高水平医院临床科研基金(2022-NHLHCRF-LX-01-0102)。

摘　　要：吸烟是多种慢性呼吸疾病、恶性肿瘤、心脑血管疾病和糖尿病等慢性非传染性疾病的“共性”危险因素,是我国当前最重要的公共卫生问题之一,而控烟是疾病防控最有效且符合成本效益的干预措施。2022年10月至2023年9月间,烟草病学领域发表了大量高质量研究,本综述选择了其中具有代表性的成果,从流行病学研究、临床研究、机制研究、控烟工作进展等方面进行综述,以期更多人更加深刻认识到“吸烟为致病之首恶,控烟为防病之首善”的理念。Smoking is one of the major risk factors for several chronic non-infectious diseases,including chronic respiratory diseases,cancers,cardiovascular diseases,and diabetes,which has become a major public health issue in China.Tobacco control is proven to be the most effective and cost-effective strategy to reduce the risk of smoking-related disease and premature death.From October 2022 to September 2023,several high quality studies on tobacco medicine have been published.This review systematically summarizes the representative studies in terms of epidemiological study,clinical study,mechanism study,and tobacco control progress.These studies further highlight the concept that"tobacco smoking is the main evil for disease and tobacco control is the main good for disease prevention",which will promote the development of tobacco medicine in China.

关 键 词：慢性非传染性疾病 流行病学研究 控烟 心脑血管疾病 疾病防控 成本效益 危险因素 恶性肿瘤 

分 类 号：R163[医药卫生—公共卫生与预防医学]